Yang Ciqiu相关文献与解析，生知库 | 链接生命科学的每一步

Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trial

新辅助安罗替尼/信迪利单抗联合化疗治疗三阴性乳腺癌（NeoSACT）：II期试验

期刊:Cell Reports Medicine

影响因子:10.6

doi:10.1016/j.xcrm.2025.102193

Zhang, Liulu; Yang, Lu; Ge, Yan; Zhu, Zhaowen; Chen, Bo; Yang, Ciqiu; Gao, Hongfei; Yang, Mei; Zhu, Teng; Wang, Kun

Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors

HER2-0 和 HER2-low 乳腺癌的差异：雄激素受体和程序性死亡配体 1 作为预测因子

期刊:Journal of Breast Cancer

影响因子:2.4

doi:10.4048/jbc.2024.0223

Zhang, Xiaoqi; Yang, Ciqiu; Chen, Yitian; Zhang, Junsheng; Li, Peiyong; Huang, Na; Chen, Yilin; Liang, Minting; Lv, Weiming; Yuan, Zhongyu; Li, Jie; Wang, Kun

Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study

基于纵向磁共振成像融合的新型模型预测接受新辅助化疗的乳腺癌患者的病理完全缓解：一项多中心回顾性研究

期刊:EClinicalMedicine

影响因子:10

doi:10.1016/j.eclinm.2023.101899

Huang, YuHong; Zhu, Teng; Zhang, XiaoLing; Li, Wei; Zheng, XingXing; Cheng, MinYi; Ji, Fei; Zhang, LiuLu; Yang, CiQiu; Wu, ZhiYong; Ye, GuoLin; Lin, Ying; Wang, Kun

Survival After Sentinel Lymph Node Biopsy Compared with Axillary Lymph Node Dissection for Female Patients with T3-4c Breast Cancer

前哨淋巴结活检与腋窝淋巴结清扫术治疗T3-4c期乳腺癌女性患者的生存率比较

期刊:Oncologist

影响因子:4.2

doi:10.1093/oncolo/oyad038

Li, Peiyong; Yang, Ciqiu; Zhang, Junsheng; Chen, Yitian; Zhang, Xiaoqi; Liang, Minting; Huang, Na; Chen, Yilin; Wang, Kun

Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment

单细胞分析揭示FOLFOX联合贝伐单抗治疗后晚期结肠癌细胞发生重编程

期刊:Frontiers in Oncology

影响因子:3.3

doi:10.3389/fonc.2023.1219642

Yang, Meiling; Yang, Ciqiu; Ma, Dong; Li, Zijun; Zhao, Wei; Yang, Dongyang

The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs

通过对配体-受体对的综合分析，定义了三阴性乳腺癌的分子亚型，并构建了配体-受体对评分模型。

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2022.982486

Pan, Weijun; Song, Kai; Zhang, Yunli; Yang, Ciqiu; Zhang, Yi; Ji, Fei; Zhang, Junsheng; Shi, Jian; Wang, Kun

Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial

低剂量阿帕替尼联合新辅助化疗治疗早期三阴性乳腺癌（LANCET）：一项单中心、单臂 II 期试验

期刊:Therapeutic Advances in Medical Oncology

影响因子:4.2

doi:10.1177/17588359221118053

Yang, Ciqiu; Zhang, Junsheng; Zhang, Yi; Ji, Fei; Chen, Yitian; Zhu, Teng; Zhang, Liulu; Gao, Hongfei; Yang, Mei; Li, Jieqing; Cheng, Minyi; Wang, Kun

New progress in early breast cancer treatment in 2021

2021年早期乳腺癌治疗取得新进展

期刊:Translational Breast Cancer Research

影响因子:1.4

doi:10.21037/tbcr-22-16

Shen, Bo; Yang, Ciqiu; Wang, Kun

127aa encoded by circSpdyA promotes FA synthesis and NK cell repression in breast cancers.

circSpdyA 编码的 127aa 可促进乳腺癌中的脂肪酸合成和 NK 细胞抑制

AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple-Negative Breast Cancer.

AKT1 磷酸化 FDX1 以促进三阴性乳腺癌细胞的铜凋亡抵抗

Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trial

新辅助安罗替尼/信迪利单抗联合化疗治疗三阴性乳腺癌（NeoSACT）：II期试验

Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors

HER2-0 和 HER2-low 乳腺癌的差异：雄激素受体和程序性死亡配体 1 作为预测因子

Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study

基于纵向磁共振成像融合的新型模型预测接受新辅助化疗的乳腺癌患者的病理完全缓解：一项多中心回顾性研究

Survival After Sentinel Lymph Node Biopsy Compared with Axillary Lymph Node Dissection for Female Patients with T3-4c Breast Cancer

前哨淋巴结活检与腋窝淋巴结清扫术治疗T3-4c期乳腺癌女性患者的生存率比较

Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment

单细胞分析揭示FOLFOX联合贝伐单抗治疗后晚期结肠癌细胞发生重编程

The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs

通过对配体-受体对的综合分析，定义了三阴性乳腺癌的分子亚型，并构建了配体-受体对评分模型。

Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial

低剂量阿帕替尼联合新辅助化疗治疗早期三阴性乳腺癌（LANCET）：一项单中心、单臂 II 期试验

New progress in early breast cancer treatment in 2021

2021年早期乳腺癌治疗取得新进展